Plasmodium Recombination of Machinery
Plasmodium Recombination of Machinery
批准号:
7834524
负责人:
Nirbhay Kumar
金额:
$40.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-05 至 2011-05-31
关键词:
ATP phosphohydrolaseAntigenic DiversityAntigenic VariationBacterial ProteinsBiochemicalCessation of lifeChemicalsChromosomal RearrangementChromosomesCo-ImmunoprecipitationsComplementary DNACulicidaeDNADNA DamageDNA RepairDNA Sequence RearrangementErythrocytesEukaryotaFoundationsFutureGene RearrangementGenesGeneticGenetic RecombinationGenomeGoalsGrowthGrowth and Development functionHomologous GeneImmuneIn VitroInfectionLeadLibrariesLife Cycle StagesLinkMalariaMediatingMediator of activation proteinMeiosisMessenger RNAMesylatesMitosisMolecularMolecular GeneticsOrganismParasitesPhage DisplayPlasmodiumPlasmodium falciparumPlayPropertyProteinsProteomicsReactionRecombinantsResearchRoleScreening procedureStagingSurfaceTestingTranscriptVaccinesWorkbasecrosslinkgene cloninghomologous recombinationimprovedinsightknockout generecombinaserecombinational repairreplication factor Aresponsetherapy developmenttransmission processvaccine development
中文摘要
疟疾寄生虫每年在全世界造成3 -5亿新感染和1- 200万人死亡。然而,有效的疫苗仍然难以捉摸,部分原因是抗原多样性和寄生虫的免疫逃避策略。重组机制与抗原变异密切相关,这一现象对开发针对疟疾寄生虫等原生动物寄生虫的疫苗至关重要。提出的研究的长期目标是研究与抗原变异等现象相关的基因重排机制。这项工作提出的一个基本原则是,了解疟原虫的重组机制将为开发治疗方法提供更好的机会。在其他真核生物中,同源重组(homologous recombination, HR)在染色体重排中起着重要作用,而细菌RecA重组酶的真核对应物Rad51和Dmc1蛋白是有丝分裂和减数分裂过程中参与同源重组的核心分子。在真核生物中,RPA和Rad54等附加蛋白与Rad51协同作用,介导HR和受损染色体的修复。提出的研究假设是,Rad51和其他相互作用的蛋白作为HR的介质,在疟原虫的生长发育过程中发挥关键作用,并促进恶性疟原虫的基因重排。恶性疟原虫中Rad51和Dmc1同源物的分子鉴定以及重组PfRad51酶学性质的最新表征,如DNA链交换和atp酶活性,都强烈表明PfRad51在这些生物体中具有保守的功能作用。我们将使用生化和遗传方法来检验我们的假设。修订后的特异性目标1和2的研究将导致HR相关蛋白的体外表征,从而探讨寄生虫重组和基因重排的生化基础。修订后的特异性目标3中的PfRad51基因敲除研究将直接评估PfRad51在寄生虫红细胞生长和var基因转录库分析中的重要性。此外,对Dmc1破坏的研究(修订的特异性目标3)将评估减数分裂特异性重组酶在疟疾传播中的作用。本研究结果对于揭示恶性疟原虫重组机制以及重组和基因重排的分子和遗传基础具有重要意义。
英文摘要
Malaria parasites, worldwide are responsible for 300-500 million new infections and 1-2 million deaths each year. An effective vaccine, however, remains elusive, partly due to antigenic diversity and the immune evasion strategies of the parasite. Recombination mechanisms are intimately linked with antigenic variation, a phenomenon of utmost significance for vaccine development against protozoan parasites like the malaria parasite. The long term objective of the proposed studies is to investigate mechanism(s) of genetic rearrangements associated with phenomenon like antigenic variation. An underlying tenet of the work proposed is that understanding the recombination mechanisms in Plasmodium will provide improved opportunities for the development of therapies. In other eukaryotes, homologous recombination (HR) plays a major role in chromosomal rearrangements, and Rad51 and Dmc1 proteins, the eukaryotic counterparts of bacterial RecA recombinase, are central molecules involved in HR during mitosis and meiosis. In eukaryotes, additional proteins like RPA and Rad54 functionally cooperate with Rad51 and mediate HR and the repair of damaged chromosomes. The hypothesis underlying proposed studies is that the Rad51 and other interacting proteins, as mediators of HR, play critical role(s) during growth and development of the parasite and facilitate gene rearrangements in P. falciparum. Molecular identification of Rad51 and Dmc1 homologues in P. falciparum and recent characterization of enzymatic properties of recombinant PfRad51, such as DNA strand exchange and ATPase activities, have strongly indicated a conserved functional role for PfRad51 in these organisms. We will test our hypothesis using biochemical as well as genetic approaches. Studies in the revised specific aims 1 and 2 will lead to in vitro characterization of the proteins involved in HR and thus probe into the biochemical basis of recombination and gene rearrangements in the parasites. PfRad51 gene knockout studies in the revised specific aim 3 will directly evaluate importance of PfRad51 in the erythrocytic growth of the parasite and analysis of repertoire of var gene transcripts. Moreover, studies on Dmc1 disruption (revised specific aim 3) will evaluate the role of meiosis specific recombinase during malaria transmission. The results of this study should be important in unraveling the recombination machinery and molecular and genetic basis for recombination and genetic rearrangements in P. falciparum.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/srep01534
发表时间:
2013
期刊:
SCIENTIFIC REPORTS
影响因子:
4.6
作者:
[Gopalakrishnan, Anusha M., Kundu, Anup K., Mandal, Tarun K., Kumar, Nirbhay]
通讯作者:
Kumar, Nirbhay
DOI:
10.1371/journal.pone.0052480
发表时间:
2012
期刊:
PloS one
影响因子:
3.7
作者:
[Mlambo G, Coppens I, Kumar N]
通讯作者:
Kumar N
Combination Vaccines to Interrupt Malaria Transmission
-
批准号:9750618
-
项目类别:
-
资助金额:$52.71万
-
财政年份:2017
-
负责人:Nirbhay Kumar
-
依托单位:
Combination Vaccines to Interrupt Malaria Transmission
-
批准号:9381629
-
项目类别:
-
资助金额:$58.19万
-
财政年份:2017
-
负责人:Nirbhay Kumar
-
依托单位:
Identification of Transmission blocking epitopes on P. vivax 48/45 protein
-
批准号:8986156
-
项目类别:
-
资助金额:$7.53万
-
财政年份:2014
-
负责人:Nirbhay Kumar
-
依托单位:
Rational Approach to Optimize Immune Potency of DNA Vaccines
-
批准号:8676649
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2013
-
负责人:Nirbhay Kumar
-
依托单位:
Rational Approach to Optimize Immune Potency of DNA Vaccines
-
批准号:8535062
-
项目类别:
-
资助金额:$20.51万
-
财政年份:2013
-
负责人:Nirbhay Kumar
-
依托单位:
Malaria Vaccine Adjuvant Immunogenicity and Safety
-
批准号:8351069
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2012
-
负责人:Nirbhay Kumar
-
依托单位:
Malaria Vaccine Adjuvant Immunogenicity and Safety
-
批准号:8515930
-
项目类别:
-
资助金额:$17.89万
-
财政年份:2012
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA vaccine to prevent transmission of human malaria
-
批准号:7893555
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2010
-
负责人:Nirbhay Kumar
-
依托单位:
Plasmodium Recombination of Machinery
-
批准号:7630336
-
项目类别:
-
资助金额:$40.49万
-
财政年份:2008
-
负责人:Nirbhay Kumar
-
依托单位:
MALARIA RESEARCH AND TRAINING PROGRAM IN ZIMBABWE
-
批准号:6395018
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
MOLECULAR DISSECTION OF P. FALCIPARUM SEXUAL DEVELOPMENT
-
批准号:6497310
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA VACCINE TO PREVENT TRANSMISSION OF HUMAN MALARIA
-
批准号:6362447
-
项目类别:
-
资助金额:$30.73万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
Malaria Training and Research Capacity Building in Southern Africa
-
批准号:8254413
-
项目类别:
-
资助金额:$14.29万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
MALARIA RESEARCH AND TRAINING PROGRAM IN ZIMBABWE
-
批准号:6531185
-
项目类别:
-
资助金额:$15.41万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA VACCINE TO PREVENT TRANSMISSION OF HUMAN MALARIA
-
批准号:6081881
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA VACCINE TO PREVENT TRANSMISSION OF HUMAN MALARIA
-
批准号:6632235
-
项目类别:
-
资助金额:$30.16万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
MALARIA RESEARCH AND TRAINING PROGRAM IN ZIMBABWE
-
批准号:6637736
-
项目类别:
-
资助金额:$14.48万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
MOLECULAR DISSECTION OF P. FALCIPARUM SEXUAL DEVELOPMENT
-
批准号:6349929
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA Vaccine to Prevent Transmission of Human Malaria
-
批准号:7884358
-
项目类别:
-
资助金额:$42.82万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
A DNA Vaccine to Prevent Transmission of Human Malaria
-
批准号:8117516
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2000
-
负责人:Nirbhay Kumar
-
依托单位:
海外基金